- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02810093
Big Data and Text-mining Technologies Applied for Breast Cancer Medical Data Analysis (SENOMETRY)
June 20, 2016 updated by: University Hospital, Strasbourg, France
SENOMETRY : Big Data and Text-mining Technologies Applied for Breast Cancer Medical Data Analysis
Primary purpose :
To develop a method to automatically extract and structure the information included in numerous medical records from breast cancer patients.
Secondary purpose :
With this procedure we can analyze the content of ten thousand anonymized textual medical records.
This information should enable us to explore many subjects, such as:
- The impact of certain therapeutic procedures
- The characteristics of sub-groups of patients
- Pregnancy associated breast cancers
- Risk factors
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
10000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Strasbourg, France, 67091
- Recruiting
- University Strasbourg Hospital
-
Contact:
- Carole Mathelin, MD
- Phone Number: 03 88 12 78 34
- Email: carole.mathelin.x@gmail.com
-
Contact:
- Karl Neuberger
- Email: kneuberger@quantmetry.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Probability Sample
Study Population
Patients (men and women) suffering from an in situ or invasive cancer treated at Hôpitaux Universitaires de Strasbourg between years 2000 and 2016.
Description
Inclusion Criteria:
- Majority (age > 18)
- Malignant breast tumors
- signed informed consent
Exclusion Criteria:
- Benign breast pathology
- Patients not initially treated at the Hôpitaux Universitaires de Strasbourg
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Breast cancer patients between 2000 and 2016
Patients treated for a breast cancer between 2000 and 2016 in the Hospital of Strasbourg (France).
|
Ten thousand medical records (between years 2000 and 2016) will be analyzed
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Validate the reliability of a computer-based, automatic information retrieval method specific to medical records from breast cancer multidisciplinary meetings
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Breast cancer recurrence rate after some therapeutic procedures
Time Frame: 6 months
|
Study of the recurrence rate of different subgroups of patients where various procedures were performed
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Carole Mathelin, MD, Strasbourg's University Hospitals
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2016
Primary Completion (Anticipated)
November 1, 2016
Study Completion (Anticipated)
December 1, 2016
Study Registration Dates
First Submitted
June 20, 2016
First Submitted That Met QC Criteria
June 20, 2016
First Posted (Estimate)
June 22, 2016
Study Record Updates
Last Update Posted (Estimate)
June 22, 2016
Last Update Submitted That Met QC Criteria
June 20, 2016
Last Verified
June 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 6373
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on retrospective medical records analyze
-
Fundació Institut de Recerca de l'Hospital de la...Completed
-
Johannes Kepler University of LinzCompleted
-
University Hospital, MontpellierRecruiting
-
Severance HospitalCompletedKidney TransplantationKorea, Republic of
-
Abramson Cancer Center at Penn MedicineActive, not recruitingProspective Follow-up of Outcomes in Patients Receiving Photodynamic Therapy for Neoplastic DiseasesNeoplastic DiseaseUnited States
-
HaEmek Medical Center, IsraelUnknownThrombosis | PrematureIsrael
-
HaEmek Medical Center, IsraelCompletedHemolytic Anemia | Thalassemia AlphaIsrael
-
Brigham and Women's HospitalAgency for Healthcare Research and Quality (AHRQ)Enrolling by invitationGastrointestinal Diseases | Heart Failure | Infections | Urologic Diseases | Shock | Hematologic Diseases | Critical Illness | Rheumatic Diseases | Asthma | Renal Failure | Neurologic Disorder | COPD Exacerbation | Cardiac Event | Oncology Problem | Arrythmia | Renal DiseaseUnited States
-
Hamad Medical CorporationCompletedChronic Kidney Diseases | Acute Kidney Injury | COVID-19 Pandemic | COVID-19 Infection | Chronic Renal Failure in ChildrenQatar
-
Peking University Third HospitalActive, not recruiting